S. Koch

发表

Deep Sequencing of Antiviral T-Cell Responses to HCMV and EBV in Humans Reveals a Stable Repertoire That Is Maintained for Many Years

F. Baas, N. de Vries, P. Klarenbeek, 2012, PLoS pathogens.

Characteristics of alloreactive T cells measured before renal transplantation

I. T. Ten Berge, S. Koch, F. Bemelman, 2012, Clinical and experimental immunology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer

S. Koch, R. Cathomas, M. Fotin‐Mleczek, 2014, BMC Cancer.

RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies vaccine in a first-in-human trial.

S. Koch, M. Fotin‐Mleczek, R. Heidenreich, 2019, Vaccine.

A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer

D. Atanackovic, Michael Thomas, S. Koch, 2019, Cancer Immunology, Immunotherapy.

Alloantigen-induced regulatory CD8+CD103+ T cells.

I. T. Ten Berge, S. Koch, R. V. van Lier, 2008, Human immunology.

Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial

R. Gottardo, Greg Finak, S. Koch, 2017, The Lancet.

Immunosenescence and Cytomegalovirus: where do we stand after a decade?

P. Griffiths, P. Moss, G. Pawelec, 2010, Immunity & Ageing.

Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer

S. Koch, R. Cathomas, M. Fotin‐Mleczek, 2019, Journal of Immunotherapy for Cancer.

Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people

Anis Larbi, Evelyna Derhovanessian, G. Pawelec, 2008, Immunity & Ageing.

Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas.

Hans-Georg Rammensee, Cécile Gouttefangeas, Arnulf Stenzl, 2009, Cancer research.

Human Immunosenescence

C. Franceschi, G. Pawelec, S. Koch, 2006, Annals of the New York Academy of Sciences.

Clonal Evolution of CD8+ T Cell Responses against Latent Viruses: Relationship among Phenotype, Localization, and Function

F. Baas, H. Pircher, A. V. van Kampen, 2014, Journal of Virology.

A novel, disruptive vaccination technology

T. Schlake, S. Koch, A. Thess, 2013, Human vaccines & immunotherapeutics.

Cytomegalovirus Infection

C. Franceschi, G. Pawelec, S. Koch, 2007, Annals of the New York Academy of Sciences.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Analysis of stem-cell-like properties of human CD161++IL-18Rα+ memory CD8+ T cells.

S. Koch, R. V. van Lier, S. Henson, 2012, International immunology.

NKp80 defines and stimulates a reactive subset of CD8 T cells.

H. Rammensee, G. Pawelec, S. Koch, 2009, Blood.

NKp 80 defines and stimulates a reactive subset of CD 8 T cells

H. Rammensee, G. Pawelec, S. Koch, 2008 .

The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays

A. Mackensen, Tania T. Køllgaard, C. Gouttefangeas, 2007, Cancer Immunology, Immunotherapy.

High frequencies of functionally impaired cytokeratin 18‐specific CD8+ T cells in healthy HLA‐A2+ donors

H. Rammensee, S. Stevanović, G. Pawelec, 2005, European journal of immunology.

Immunorejuvenation in the elderly.

G. Pawelec, S. Koch, C. Gouttefangeas, 2006, Rejuvenation research.

Distinct transcriptional changes in non-small cell lung cancer patients associated with multi-antigenic RNActive® CV9201 immunotherapy

O. Kohlbacher, J. Billingsley, S. Koch, 2016, Oncoimmunology.

Messenger RNA vaccination and B-cell responses in NSCLC patients.

D. Atanackovic, S. Koch, F. Mayer, 2012 .

Maintenance immunosuppressive therapy with everolimus preserves humoral immune responses.

A. Zwinderman, S. Koch, F. Bemelman, 2010, Kidney international.

Human cytomegalovirus infection and T cell immunosenescence: A mini review

G. Pawelec, S. Koch, R. Solana, 2006, Mechanisms of Ageing and Development.

1149PResults of the randomized, placebo-controlled phase I/IIB trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)

S. Koch, A. Stenzl, Y. Loriot, 2017 .

Session 16: Ageing and the immune system in vivo

C. Franceschi, G. Pawelec, S. Koch, 2004 .

Immunosenescence, suppression and tumour progression

G. Pawelec, S. Koch, C. Gouttefangeas, 2006, Cancer Immunology, Immunotherapy.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.